



The Commonwealth of Massachusetts  
Executive Office of Health and Human Services  
Department of Public Health  
State Laboratory Institute  
305 South Street, Jamaica Plain, MA 02130

MITT ROMNEY  
GOVERNOR

KERRY HEALEY  
LIEUTENANT GOVERNOR

TIMOTHY R. MURPHY  
SECRETARY

PAUL J. COTE, JR.  
COMMISSIONER

Bureau of Communicable Disease Control  
(617) 983-6800

### Memorandum

**To:** Health Insurers and Health Plans

**From:** Robert W. Morrison, Vaccine Manager  
Marie O'Donnell, Acting Immunization Program Manager

**Date:** August 2005

**Re:** Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccines

The Food and Drug Administration recently licensed two Tdap vaccines for use as a single booster dose. Boostrix®, manufactured by GlaxoSmithKline, is approved for use in adolescents 10 through 18 years of age. Adacel™, manufactured by sanofi pasteur, is approved for use in persons 11 through 64 years of age.

#### **Advisory Committee on Immunization Practices (ACIP) Recommendations**

The ACIP voted to recommend a single dose of Tdap in place of the tetanus-diphtheria (Td) for booster immunization as outlined below:

1. Routine immunization of adolescents 11-12 years of age. In addition, a single dose of Tdap should be given to adolescents 13 through 18 who have not yet received Td.
2. ACIP encourages use in adolescents 11 to 18 who have already received Td to provide protection against pertussis.
3. Tdap, instead of Td, should be used for un- or under-vaccinated adolescents for wound prophylaxis, outbreak settings and exposure to pertussis.

The final ACIP recommendations for the use of Tdap in adolescents have not been published but interim recommendations can be found at <http://www.cdc.gov/nip/vaccine/tdap/default.htm>.

Adacel™ has been licensed for use as a single booster dose in adults. The ACIP has not issued recommendations for this group, but is expected to sometime this fall.

### **Tdap Supplied by Massachusetts Department Public Health**

MDPH will only supply Tdap for the routine immunization of adolescents 11-12 years of age and those adolescents 13 through 18 who missed the 11-12 year Td dose (#1 above). MDPH will not be supplying Tdap for use in the other groups (#2 and #3 above) or for adults.

In early fall 2005, MDPH plans to purchase one of the two formulations of this vaccine and begin distribution to pediatric healthcare providers.

The current procedural terminology (CPT) code for both Boostrix® and Adacel™ is 90715. Since providers will need to purchase Tdap vaccine privately to augment state-supplied vaccine for the recommended age groups, this code should be used for reimbursement.

We will keep you updated on the availability of state-supplied Tdap vaccine. If you have any questions regarding vaccine availability please contact the MDPH Vaccine Management Unit at 617-983-6828.